Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesNo recent work listed

Akira Chikamoto

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112548097, A5113352460. Sources: OpenAlex.

Their work

Papers
24 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 4 papers · 2017: 2 papers · 2018: 6 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper

Papers 24

  1. Survival Impact of Perioperative Red Blood Cell Transfusion During Pancreatectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Propensity Score Matchin… Co-author DOI 10.1097/mpa.0000000000001997↗
  2. Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study. Co-author DOI 10.1245/s10434-020-09022-3↗
  3. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients underg… Co-author DOI 10.1007/s00595-019-01866-x↗
  4. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  5. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. Co-author DOI 10.1007/s00535-018-01535-9↗
  6. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Co-author DOI 10.1111/cas.13874↗
  7. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2017.08.016↗
  8. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Unde… Co-author DOI 10.1097/mpa.0000000000001146↗
  9. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Co-author DOI 10.1111/cas.13467↗
  10. Multiple Primary Cancers in Patients with Pancreatic Cancer. Co-author DOI 10.1177/000313481808401205↗
  11. Thoracic wall muscle metastasis from pancreatic cancer. Co-author DOI 10.1186/s40792-017-0393-0↗
  12. Cystic gastric metastasis from pancreatic cancer. Co-author DOI 10.1186/s40792-018-0443-2↗
  13. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? First author DOI 10.1097/mpa.0000000000000897↗
  14. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-5799-1↗
  15. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. Co-author DOI 10.1007/s00595-015-1238-8↗
  16. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases. Co-author DOI 10.1007/s10147-016-0975-z↗
  17. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000624↗
  18. EDUCATION AND IMAGING. Hepatobiliary and Pancreatic: Rapid growing cystic ovarian metastasis from pancreatic cancer. Co-author DOI 10.1111/jgh.13164↗
  19. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Co-author DOI 10.1111/cas.12732↗
  20. Impact of Postoperative Weight Loss on Survival After Resection for Pancreatic Cancer. First author DOI 10.1177/0148607114520992↗
  21. Pancreatic cancer in the remnant pancreas following primary pancreatic resection. First author DOI 10.1007/s00595-013-0708-0↗
  22. Hepatobiliary and pancreatic: sigmoidal mesenterial lymph node metastasis from pancreatic cancer. Co-author DOI 10.1111/jgh.12807↗
  23. Dynamic computed tomography of locally advanced pancreatic cancer: effect of low tube voltage and a hybrid iterative reconstruction algorithm on image quality. Co-author DOI 10.1097/rct.0b013e318296db2b↗
  24. An autopsy study to clarify characteristics of local recurrence after extended pancreatectomy with intraoperative radiation therapy in patients with pancreatic… Co-author DOI 10.1007/s00423-012-0934-8↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daisuke Hashimoto · 16 shared papers, 2014–2019 · strength 1.01
  2. Katsunori Imai · 11 shared papers, 2015–2022 · strength 0.88
  3. Shigeki Nakagawa · 11 shared papers, 2015–2019 · strength 0.77
  4. Kota Arima · 10 shared papers, 2016–2020 · strength 0.68
  5. Hideo Baba · 10 shared papers, 2014–2020 · strength 0.64
  6. Yuki Kitano · 7 shared papers, 2016–2022 · strength 0.58
  7. Hirohisa Okabe · 8 shared papers, 2015–2021 · strength 0.55
  8. Hiromitsu Hayashi · 6 shared papers, 2014–2022 · strength 0.51
  9. Takanobu Yamao · 6 shared papers, 2018–2021 · strength 0.50
  10. Tatsunori Miyata · 6 shared papers, 2018–2021 · strength 0.49
  11. Masayo Tsukamoto · 6 shared papers, 2018–2021 · strength 0.49
  12. Rumi Itoyama · 5 shared papers, 2014–2022 · strength 0.48
  13. Naoki Umezaki · 6 shared papers, 2018–2020 · strength 0.47
  14. Takayoshi Kaida · 5 shared papers, 2016–2022 · strength 0.37
  15. Kensuke Yamamura · 5 shared papers, 2016–2018 · strength 0.34
  16. Masahiko Hirota · 5 shared papers, 2014–2019 · strength 0.30
  17. Hidetoshi Nitta · 5 shared papers, 2015–2018 · strength 0.29
  18. Hideo Baba · 3 shared papers, 2017–2022 · strength 0.28
  19. Takatsugu Ishimoto · 3 shared papers, 2018–2019 · strength 0.21
  20. Yosuke Nakao · 2 shared papers, 2020–2021 · strength 0.21
  21. Hideo Baba · 4 shared papers, 2012–2018 · strength 0.19
  22. Hideo Baba · 3 shared papers, 2016–2018 · strength 0.18
  23. Hirohisa Okabe · 2 shared papers, 2018–2020 · strength 0.17
  24. Masafumi Inomata · 2 shared papers, 2019 · strength 0.15
  25. Takashi Matsumoto · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.